Roth Capital Lowers vTv Therapeutics (VTVT) to Neutral

Roth Capital cut shares of vTv Therapeutics (NASDAQ:VTVT) from a buy rating to a neutral rating in a research report released on Tuesday, Marketbeat Ratings reports. Roth Capital currently has $17.00 price target on the biotechnology company’s stock, down from their prior price target of $18.00.

Several other research firms also recently commented on VTVT. Northland Securities initiated coverage on vTv Therapeutics in a report on Thursday, February 8th. They set an outperform rating and a $28.00 price objective on the stock. Zacks Investment Research cut vTv Therapeutics from a hold rating to a sell rating in a research report on Saturday, March 3rd. Canaccord Genuity set a $15.00 target price on vTv Therapeutics and gave the company a buy rating in a research report on Thursday, December 21st. Seaport Global Securities initiated coverage on vTv Therapeutics in a research report on Thursday, March 29th. They set a buy rating and a $14.00 target price on the stock. Finally, Stifel Nicolaus cut vTv Therapeutics from a buy rating to a hold rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. vTv Therapeutics has an average rating of Hold and a consensus target price of $13.69.

VTVT opened at $0.80 on Tuesday. The firm has a market cap of $23.44, a price-to-earnings ratio of -0.48 and a beta of 1.74. vTv Therapeutics has a 52 week low of $0.65 and a 52 week high of $8.40. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of -0.10.



vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.03). The business had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.10 million. equities research analysts forecast that vTv Therapeutics will post -1.48 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning bought a new stake in vTv Therapeutics during the 4th quarter valued at $114,000. Millennium Management LLC bought a new stake in vTv Therapeutics during the 4th quarter valued at $377,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the 3rd quarter valued at $481,000. State Street Corp boosted its position in vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Royce & Associates LP bought a new stake in vTv Therapeutics during the 4th quarter valued at $1,352,000. 11.20% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Roth Capital Lowers vTv Therapeutics (VTVT) to Neutral” was published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://dakotafinancialnews.com/2018/04/13/roth-capital-lowers-vtv-therapeutics-vtvt-to-neutral.html.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply